ArticlePloS one2011
Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
131 citing papers in PubMed, 266 citations in OpenAlex.
- Phage anti-defense genes targeting NADVirulence · 2026Article
- Training a phage to expand its host range: directed evolution againstAntimicrobial agents and chemotherapy · 2026Article
- Albumin Hydrogels Loading Bacteriophage PA57 as a Promising Platform forGels (Basel, Switzerland) · 2026Article
- Phage therapy: from basic biology to clinical application.Nature reviews. Microbiology · 2026Review
- Directed evolution of phage Romulus in biofilm-embeddedBiofilm · 2026Article
- Bacteriophages as Therapeutic Agents for Pulmonary Infections: From Biological Principles to Clinical Applications.Pharmaceutics · 2026Review
- The Role of Genomics in Advancing and Standardising Bacteriophage Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Bacteriophage Therapy in Cystic Fibrosis: Emerging Strategies for Managing ChronicDrug design, development and therapy · 2026Review
- Detectable effects of bacterial phylogeny on virulence but not phage efficacy in anISME communications · 2026Article
- Design of Specific Peptide Inhibitors of Toxin-Antitoxin-Mediated Antiphage Defense.ACS synthetic biology · 2025Article
- Development of an inhalable dry powder of mycobacteriophage D29 using thin-film freeze-drying.International journal of pharmaceutics · 2025Article
- Therapeutic Optimization ofViruses · 2025Article
- Antibiotic-ResistantMicroorganisms · 2025Review
- Isolation and characterization of new lytic bacteriophage PSA-KC1 against Pseudomonas aeruginosa isolates from cystic fibrosis patients.Scientific reports · 2025Article
- Sustainable AGP alternatives: a systems approach to non-antibiotic growth regulators standardization, synergistic formulation and environmental safety.Frontiers in veterinary science · 2025Review
- Predatory bacteria can intensify lung-injury in a multidrug-resistantFrontiers in microbiology · 2025Article
- Harnessing the human gut microbiota: an emerging frontier in combatting multidrug-resistant bacteria.Frontiers in immunology · 2025Review
- Challenges and opportunities of phage therapy forApplied and environmental microbiology · 2024Review
- Phage therapy could be key to conquering persistent bacterial lung infections in children.npj antimicrobials and resistance · 2024Review
- Pharmacokinetics and pharmacodynamics of bacteriophage therapy: a review with a focus on multidrug-resistant Gram-negative bacterial infections.Clinical microbiology reviews · 2024Review
71 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multidrug-resistant bacteria are the cause of an increasing number of deadly pulmonary infections. Because there is currently a paucity of novel antibiotics, phage therapy--the use of specific viruses that infect bacteria--is now more frequently being considered as a potential treatment for bacterial infections. Using a mouse lung-infection model caused by a multidrug resistant Pseudomonas aeruginosa mucoid strain isolated from a cystic fibrosis patient, we evaluated bacteriophage treatments. New bacteriophages were isolated from environmental samples and characterized. Bacteria and bacteriophages were applied intranasally to the immunocompetent mice. Survival was monitored and bronchoalveolar fluids were analysed. Quantification of bacteria, bacteriophages, pro-inflammatory and cytotoxicity markers, as well as histology and immunohistochemistry analyses were performed. A curative treatment (one single dose) administrated 2 h after the onset of the infection allowed over 95% survival. A four-day preventive treatment (one single dose) resulted in a 100% survival. All of the parameters measured correlated with the efficacy of both curative and preventive bacteriophage treatments. We also showed that in vitro optimization of a bacteriophage towards a clinical strain improved both its efficacy on in vivo treatments and its host range on a panel of 20 P. aeruginosa cystic fibrosis strains. This work provides an incentive to develop clinical studies on pulmonary bacteriophage therapy to combat multidrug-resistant lung infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.